Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05617677 · ClinicalTrials.gov registry record · Phase 3
A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)
A Phase 3 study of Systemic Lupus Erythematosus, sponsored by Bristol-Myers Squibb.
- Active
- Registry status
- Phase 3
- Development phase
- 516
- Enrollment target
- 20
- Study locations
NCT05617677: Active Phase 3 study of Systemic Lupus Erythematosus, sponsored by Bristol-Myers Squibb.
NCT05617677 is a Phase 3 study of Systemic Lupus Erythematosus that is active but no longer recruiting, run by Bristol-Myers Squibb. The registered enrollment target is 516 participants, above the 375-participant average among 99 other Systemic Lupus Erythematosus trials with a reported enrollment target (38% higher). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05617677, a Phase 3 study of Systemic Lupus Erythematosus, is active but no longer recruiting, sponsored by Bristol-Myers Squibb.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 516 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the effectiveness and safety of deucravacitinib compared with placebo in an active moderate to severe Systemic Lupus Erythematosus (SLE) population.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Deucravacitinib
Study Locations (20)
California
- Kaiser Permanente - Fontana
- Local Institution - 0247 - La Mesa
- Local Institution - 0090 - La Palma
- Local Institution - 0124 - Los Angeles
- Local Institution - 0248 - Sacramento
- Local Institution - 0253 - San Diego
- Local Institution - 0128 - Santa Barbara
Florida
- Local Institution - 0249 - Coral Springs
- Local Institution - 0010 - Gainesville
- Local Institution - 0087 - Miami
- Local Institution - 0007 - Orlando
- Local Institution - 0242 - Plantation
- Local Institution - 0002 - Tamarac
- Local Institution - 0165 - Tampa
Arizona
- Local Institution - 0229 - Phoenix
- Local Institution - 0193 - Tucson
Alabama
- Local Institution - 0012 - Birmingham
Colorado
- Local Institution - 0099 - Denver
Connecticut
- Local Institution - 0054 - New Haven
Georgia
- Local Institution - 0204 - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 516 participants |
| Start Date | 2023-01-12 |
| Est. Completion | 2028-11-13 |
| Phase | Phase 3 |
What the registry record for NCT05617677 still lists
NCT05617677 is an interventional study that assigns participants to a tested intervention. The registered 516 participants enrollment target is mid-sized for trials with a published cap, above the 375-participant average among 99 other Systemic Lupus Erythematosus trials with a reported enrollment target (38% higher).
The record links to 1 condition, with Systemic Lupus Erythematosus appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05617677 names 20 study sites across 7 states, led by California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT05617677 about?
NCT05617677 is a clinical study titled "A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)". The purpose of this study is to evaluate the effectiveness and safety of deucravacitinib compared with placebo in an active moderate to severe Systemic Lupus Erythematosus (SLE) population.
What is the current status of trial NCT05617677?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 516 participants. The study started on 2023-01-12. Estimated completion is 2028-11-13.
What conditions does trial NCT05617677 study?
This clinical trial studies the following conditions: Systemic Lupus Erythematosus.
What interventions are being tested in trial NCT05617677?
The interventions under investigation include: Placebo (OTHER), Deucravacitinib (DRUG).
Who is sponsoring clinical trial NCT05617677?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05617677 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Systemic Lupus Erythematosus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05617677's enrollment target sits among peer trials
516 15th of 99 higher than 85 of 99 other Systemic Lupus Erythematosus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Systemic Lupus Erythematosus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus
RECRUITING · Phase 3
-
Effects of Stopping Hydroxychloroquine in Elderly Lupus Disease
RECRUITING · Phase 3
-
An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
RECRUITING · Phase 3
-
Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
RECRUITING · Phase 3
-
A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05933083 · 516 participants · NA
MCNAIR Study: coMparative effeCtiveness of iN-person and teleheAlth cardIac Rehabilitation
- NCT05676450 · 517 participants · NA
Feasibility and Clinical Utility of Cell-free DNA (cfDNA) in Identifying Actionable Alterations and Minimal Residual Disease for Lymphoma Patients Across Community Centers in Texas
- NCT05577819 · 515 participants · NA
Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEF
- NCT06804837 · 515 participants · NA
Implement and Test Visual Consent Template and Process
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI